Searched for
ZYDUS LUPIN
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- 6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation i...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- India Inc's foreign investments more than double in AprilIndian companies significantly boosted overseas investments in April. Direct investments surged to $3.37 billion, more than doubling from M...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Zydus partners with Lupin to co-market generic semaglutide in IndiaZydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide ...
- Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in IndiaZydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and a...
- Stocks to buy today: Wipro gets downgraded post Q4 results; Lupin could see over 20% upsideBrokerages are showing caution on specific stocks due to factors impacting earnings visibility. Nuvama downgraded Wipro to "Hold," citing w...
- Time to buy pharma? 3 stocks Forum Parekh is betting onZydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life wil...
- Zydus, Lupin enter licensing pact to market drug to treat liver diseaseZydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing...
- Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar MgLupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by Ind...
- Zydus Lifesciences, Lupin recall products in US market owing to manufacturing issuesZydus initiated the Class II voluntary recall on July 15 this year. Similarly, Baltimore-based Lupin Pharmaceuticals, Inc, is recalling 7,8...
- Indoco in talks to sell part of India operationsIndoco’s domestic formulations sales for the year ended March 31, 2018, were flat at Rs 595 crore, as against Rs 585 crore last year (growt...
Load More
